July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
CD109: a novel marker for Ocular Surface Squamous Neoplasia differentiation
Author Affiliations & Notes
  • Prisca Raquel Bustamante
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • Jade Marie Lasiste
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • Denise Miyamoto
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • sabrina bergeron
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • Christina Mastromonaco
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • Laura Nuñez
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • Miguel N Burnier
    Pathology , MUHC McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Prisca Bustamante, None; Jade Lasiste, None; Denise Miyamoto, None; sabrina bergeron, None; Christina Mastromonaco, None; Laura Nuñez, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5596. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Prisca Raquel Bustamante, Jade Marie Lasiste, Denise Miyamoto, sabrina bergeron, Christina Mastromonaco, Laura Nuñez, Miguel N Burnier; CD109: a novel marker for Ocular Surface Squamous Neoplasia differentiation. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5596.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : CD109 is a transmembrane protein that binds to TGF-β and inhibits TGF-β/Smad signaling. CD109 expression has been detected predominantly in squamous cell carcinoma (SCC) and its expression is higher in well-differentiated tumors. Ocular surface squamous neoplasia (OSSN) encompasses a spectrum of precancerous and malignant lesions of the conjunctiva. OSSN ranges from dysplasia to conjunctival intraepithelial neoplasia (CIN) I (mild), II (moderate) or III (severe), to SCC which is the most frequent malignancy of the conjunctiva. The aim of this study is to evaluate CD109 expression in OSSN to determine if its presence is related to spectrum progression.

Methods : Automated immunohistochemistry using anti-CD109 was performed in 20 OSSN case series: CIN I-II (n=9), CIN III (n=5), SCC (n=6), and normal epithelium (NE; n=5). Cutaneous melanomas were used as a positive control. Slides were analyzed using Aperio Positive Pixel Count algorithm. In addition, an ocular pathologist manually evaluated positivity based on a scale from 0 to 2 (0=negative, 1=mild, 2=intense). Staining extent was classified as 1=focal or 2=diffuse. Extent and intensity were converted to the German Immunoreactive Score; a score 2 or higher was considered positive. Statistical analysis was performed using Mann-Whitney and Fisher exact test; P<0.05 was considered significant.

Results : CD109 positivity was detected in all OSSN cases. Expression in OSSN was statistically higher than in NE (P=0.0008). Using the automated software, expression was significantly greater in all lesions (CIN I-II [P=0.001], CIN III [P=0.007], SCC [P=0.043]) compared to NE. According to the manual analysis, there was a statistically significant difference in CIN I-II (P=0.005), CIN III (P=0.04) and SCC (P=0.454) compared to NE. No significant differences in expression between CIN I-II vs CIN III or SCC were found. No correlation between age and CD109 expression was found (r=0.152).

Conclusions : To the best of our knowledge, this is the first study assessing expression of CD109 in OSSN. The similar results obtained using both software and manual evaluation validates the automated analysis. CD109 upregulation suggests an involvement in the pathogenesis of OSSN. Further studies are necessary to investigate the role of CD109 in the progression of CIN to SCC in the conjunctiva and as a possible therapeutic target.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×